Precision Medicine for Gastric Cancer: Current State of Organoid Drug Testing
Gastric cancer (GC) presents a significant health challenge and ranks as the fifth most common cancer in the world. Unfortunately, most patients with GC exhaust standard care treatment options due to late diagnosis and tumour heterogeneity that leads to drug resistance, resulting in poor survival ou...
Saved in:
| Main Authors: | Tharindie N. Silva, Josephine A. Wright, Daniel L. Worthley, Susan L. Woods |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Organoids |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2674-1172/3/4/16 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Advancing precision medicine in esophageal squamous cell carcinoma using patient-derived organoids
by: Suya Shen, et al.
Published: (2024-12-01) -
Advances in the application of colorectal cancer organoids in precision medicine
by: Yanan Zhang, et al.
Published: (2024-12-01) -
Progress in the development of ovarian cancer organoids and their application in drug testing
by: Dong CHEN, et al.
Published: (2021-08-01) -
Standard: Human gastric organoids
by: Fan Hong, et al.
Published: (2025-01-01) -
Precision Treatment of Metachronous Multiple Primary Malignancies Based on Constructing Patient Tumor-Derived Organoids
by: Yicheng Wang, et al.
Published: (2024-11-01)